The 3 Years Overall Survival Rate in the Women with Stage III Endometrial Cancer across Different Sequences of Adjuvant Chemotherapy or Radiation Therapy
Article Sidebar
Main Article Content
Abstract
Objectives: To analyze the three years overall survival (OS) and progression free survival (PFS) in women with stage III endometrial cancer across different sequences of chemotherapy (CT) and radiotherapy (RT).
Materials and Methods: A total of 110 stage III endometrial cancer (EC) patients treated with surgically staging and postoperatively received adjuvant therapy in the sandwich method were retrospectively analyzed. Treatment protocols were divided into three groups (Group A: 1-2 cycles of CT followed by RT and 4-5 cycles of CT, Group B: 3 cycles of CT before RT and 3 cycles of CT, and Group C: 4-5 cycles of CT before RT and 1-2 cycles of CT). Survival analysis was analyzed by log-rank test and Cox regression analysis.
Results: After 68 months of median follow-up time, the three years OS and PFS in all patients were 90.0% and 93.5%, respectively. There was no statistical difference in OS and PFS among the three groups. The three years OS was 100%, 86.8%, and 94.7% in groups A, B, and C. In addition, consecutively, the three years PFS was 100%, 91.88%, and 94.7% in groups A, B, and C.
Conclusion: Different adjuvant chemotherapy or radiation therapy sequences offer excellent clinical efficacy and no treatment-related mortality in stage III EC. Moreover, sequences of CT and RT in the sandwich method did not impact the three years OS and PFS.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Lederman J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016;27:16-41.
De Boer SM, Nout RA, Bosse T, Creutzberg CL. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Rev Anticancer Ther 2019;19:51-60.
Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95:266-71.
Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, et al. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol 2016;141:421-7.
Secord AA, Havrilesky LJ, O’Malley DM, Bae-Jump V, Fleming DN, Broadwater G, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009;114:442-7.
Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high-risk endometrial carcinoma. Gynecol Oncol 2010;118:19-23.
Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus “sandwich” sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. Gynecol Oncol 2015;137:28-33.
Gao H, Zhang Z. Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis. Medicine (Baltimore) 2015;94:e672.
Bie Y, Zhang Z, Wang X. Adjuvant chemo-radiotherapy in the “sandwich” method for high risk endometrial cancer--a review of literature. BMC Womens Health 2015;15:50-4.
Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus “sandwich” sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma, Gynecol. Oncol 2015;137:28–33.
Modh A, Ghanem AI, Burmeister C, Hanna RK, Elshaikh MA. What is the optimal adjuvant treatment sequence for node-positive endometrial cancer? Results of a national cancer database analysis. Int J Gynecol Cancer 2018;28:248–53.
Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2008;108:201-6.
Geller MA, Ivy JJ, Ghebre R, Downs LS, Judson PL, Carson LF, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011;121:112-7.
Onal C, Sari SY, Yildirim BA, Yavas G, Gultekin M, Guler OC, et al. A multi-institutional analysis of sequential versus “sandwich” adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma. J Gynecol Oncol 2019;30:e28.
Alvarez Secord A, Havrilesky LJ, Bae-Jump V, Chin J, Calingaert B, Bland A, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007;107:285-91.
Lupe K, D’Souza DP, Kwon JS, Radwan JS, Harle IA, Hammond JA, et al. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol 2009;114:94-8.
Abaid LN, Rettenmaier MA, Brown JV, Micha JP, Mendivil AA, Wabe MA, et al. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. J Gynecol Oncol 2012;23:22-7.
Lan C, Huang X, Cao X, Huang H, Feng Y, Huang Y, et al. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a “sandwich” protocol in patients with advanced endometrial cancer: a single-institution experience. Expert Opin Pharmacother 2013;14:535-42.